C07D 277/28
Radicals substituted by nitrogen atoms
C07D277/28 (Radicals substituted by nitrogen atoms) appears on 741 US grants and 789 published applications in this corpus.
Search patents in C07D- Granted patents
- 741
- Published applications
- 789
- Assignees
- 452
- Inventors
- 2,758
- Latest grant
- 14 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 4 | 0 |
| 1977 | 2 | 0 |
| 1978 | 4 | 0 |
| 1979 | 3 | 0 |
| 1980 | 3 | 0 |
| 1981 | 3 | 0 |
| 1982 | 4 | 0 |
| 1983 | 7 | 0 |
| 1984 | 6 | 0 |
| 1985 | 1 | 0 |
| 1986 | 5 | 0 |
| 1987 | 5 | 0 |
| 1988 | 6 | 0 |
| 1989 | 4 | 0 |
| 1990 | 14 | 0 |
| 1991 | 11 | 0 |
| 1992 | 12 | 0 |
| 1993 | 17 | 0 |
| 1994 | 17 | 0 |
| 1995 | 10 | 0 |
| 1996 | 24 | 0 |
| 1997 | 32 | 0 |
| 1998 | 13 | 0 |
| 1999 | 11 | 0 |
| 2000 | 15 | 0 |
| 2001 | 15 | 8 |
| 2002 | 20 | 20 |
| 2003 | 17 | 38 |
| 2004 | 16 | 44 |
| 2005 | 20 | 38 |
| 2006 | 20 | 37 |
| 2007 | 31 | 44 |
| 2008 | 24 | 43 |
| 2009 | 16 | 35 |
| 2010 | 19 | 40 |
| 2011 | 24 | 30 |
| 2012 | 26 | 26 |
| 2013 | 17 | 34 |
| 2014 | 29 | 48 |
| 2015 | 42 | 33 |
| 2016 | 28 | 40 |
| 2017 | 26 | 28 |
| 2018 | 19 | 29 |
| 2019 | 21 | 17 |
| 2020 | 17 | 25 |
| 2021 | 7 | 21 |
| 2022 | 14 | 28 |
| 2023 | 9 | 23 |
| 2024 | 13 | 19 |
| 2025 | 12 | 22 |
| 2026 | 6 | 19 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Compounds and their uses as CD38 inhibitors14 Jul 2026US 12,679,832 B2Nanjing Immunophage Biotech Co., Ltd.
- Small molecule prostagladin transport inhibitors19 May 2026US 12,630,515 B2Albert Einstein College of Medicine
- Hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof31 Mar 2026US 12,590,071 B2Korea Institute of Science and Technology
- Compound, production method therefor, and pharmaceutical composition10 Mar 2026US 12,570,618 B2National Cancer Center
- Methods and compositions for targeting Tregs using CCR8 inhibitors17 Feb 2026US 12,552,753 B2Nanjing Immunophage Biomedical Co., Ltd.
- Therapeutic compounds1 Oct 2026US 2026/0297016 A1Regents of the University of Minnesota
- Hdac1/2 selective inhibitor and use thereof1 Oct 2026US 2026/0297110 A1Wigen Biomedicine Technology (Shanghai) Co., Ltd.
- Compounds for positive modulation of the autophagy-lysosomal pathway and methods of use27 Aug 2026US 2026/0250256 A1
- 3-aryloxy-3-aryl-propylamine compound and uses thereof20 Aug 2026US 2026/0242364 A1Shanghai Leado Pharmatech Co. Ltd.
- Nematicidal compounds, their composition and use thereof13 Aug 2026US 2026/0231945 A1
Most cited
By later US patents
- Retroviral protease inhibiting compounds159US 5,142,056 AAbbott Laboratories · 1992
- Platinum complex and light emitting device154US 7,442,797 B2Takasago International Corporation · 2008
- Arylsulfonamido-substituted hydroxamic acids110US 5,455,258 ACiba-Geigy Corporation · 1995
- Retroviral protease inhibiting compounds109US 5,354,866 AAbbott Laboratories · 1994
- Azo amino acids derivatives100US 6,528,533 B2Vertex Pharmaceuticals Incorporated · 2003